Synthesis and Evaluation of a Monomethyl Auristatin E─Integrin α<sub>v</sub>β<sub>6</sub> Binding Peptide–Drug Conjugate for Tumor Targeted Drug Delivery

Ryan A. Davis, Tanushree Ganguly, Rebecca Harris, Sven H. Hausner, Luciana Kovacs, Julie L. Sutcliffe

Journal of Medicinal Chemistry · 2023 · 31 citations · 36 references

DOIFull text

Open access

Concepts

Abstract

High Resolution Image Download MS PowerPoint Slide Many anticancer drugs exhibit high systemic off-target toxicities causing severe side effects. Peptide–drug conjugates (PDCs) that target tumor-specific receptors such as integrin α v β 6 are emerging as powerful tools to overcome these challenges. The development of an integrin α v β 6 -selective PDC was achieved by combining the therapeutic efficacy of the cytotoxic drug monomethyl auristatin E with the selectivity of the α v β 6 -binding peptide (α v β 6 -BP) and with the ability of positron emission tomography (PET) imaging by copper-64. The [ 64 Cu]PDC- 1 was produced efficiently and in high purity. The PDC exhibited high human serum stability, integrin α v β 6 -selective internalization, cell binding, and cytotoxicity. Integrin α v β 6 -selective tumor accumulation of the [ 64 Cu]PDC- 1 was visualized with PET-imaging and corroborated by biodistribution, and [ 64 Cu]PDC- 1 showed promising in vivo pharmacokinetics. The [ nat Cu]PDC- 1 treatment resulted in prolonged survival of mice bearing α v β 6 (+) tumors (median survival: 77 days, vs α v β 6 (−) tumor group 49 days, and all other control groups 37 days).

References

36